List of nationally authorised medicinal products
|
|
- Edward Cox
- 5 years ago
- Views:
Transcription
1 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 , NL/H/4274/ /11/00/32 NOVARTIS PHARMA N.V. LU solution pour inhalation par nébuliseur TOBI 300 mg/5 ml NL/H/4274/ /11/00/32 NOVARTIS PHARMA N.V. LU TOBI 300 mg/5 ml NL/H/4274/001 BE NOVARTIS PHARMA N.V. BE Tobi NL/H/4274/ NOVARTIS HEALTHCARE A/S DK Tobi 300 mg/5 ml solução para inalação por nebulização solución para inhalación por nebulizador Tobi 300 mg/5 ml sumutinliuos lösning för nebulisator TOBI 300 mg/5 ml Διάλυμα για εισπνοή με εκνεφωτή TOBI 300 mg/5 ml Διάλυμα για εισπνοή με εκνεφωτή TOBI 300 mg/5 ml Διάλυμα για εισπνοή με εκνεφωτή Tobi 300 mg/5 ml oldat porlasztásra NL/H/4274/ NOVARTIS FARMA - PRODUTOS FARMACÊUTICOS S.A. NL/H/4274/ NOVARTIS FARMACÉUTICA S.A. NL/H/4274/ NOVARTIS EUROPHARM LIMED NL/H/4274/ NOVARTIS FINLAND OY FI NL/H/4274/ NOVARTIS FINLAND OY FI NL/H/4274/ NOVARTIS (HELLAS) S.A.C.I. NL/H/4274/ NOVARTIS (HELLAS) S.A.C.I. NL/H/4274/ NOVARTIS (HELLAS) S.A.C.I. not available OGYI-T-8707/01 NOVARTIS NGÁRIA KFT. PHARMA PT ES GR GR GR EMA/615391/2018 Page 2/9
3 Tobi 300 mg/5 ml oldat porlasztásra Tobi 300 mg/5 ml oldat porlasztásra Tobi 300 mg/5 ml - inhalasjonsvæske til nebulisator, oppløsning TOBI 300 mg/5 ml nebuliser solution/ ТОБИ 300mg/5ml разтвор за пулверизиране verneveloplossing Tobi 300 mg/5 ml verneveloplossing, solution pour inhalation par nébuliseur soluţie pentru inhalare prin nebulizator soluţie pentru inhalare prin nebulizator soluţie pentru inhalare prin nebulizator not available OGYI-T-8707/02 NOVARTIS NGÁRIA KFT. PHARMA not available OGYI-T-8707/03 NOVARTIS NGÁRIA KFT. PHARMA NL/H/4274/ NOVARTIS PHARMA AT NL/H/4274/ NOVARTIS NORGE AS NO NL/H/4274/ NOVARTIS PHARMA DE not available NOVARTIS PHARMA BG NL/H/4274/001 BE NOVARTIS PHARMA N.V. BE NL/H/4274/001 RVG NOVARTIS PHARMA B.V. NL NL/H/4274/001 BE NOVARTIS PHARMA N.V. BE not available 8377/2015/01 NOVARTIS PHARMA RO not available 8377/2015/02 NOVARTIS PHARMA RO not available 8377/2015/03 NOVARTIS PHARMA RO EMA/615391/2018 Page 3/9
4 Tobi 300mg/5ml,solution pour inhalation par nébuliseur Tobi 300mg/5ml,solution pour inhalation par nébuliseur Tobi 300mg/5ml,solution pour inhalation par nébuliseur roztok pre rozprašovač TOBI 300 mg/5 ml, lösning för nebulisator TOBI 300 mg/5 ml Tobi διάλυμα για εισπνοή με εκνεφωτή 300mg/5ml BRAMOB 300 mg/4 ml BRAMOB 300 mg/4 ml BRAMOB 300 mg/4 ml NL/H/4274/ NOVARTIS PHARMA S.A.S. FR NL/H/4274/ NOVARTIS PHARMA S.A.S. FR NL/H/4274/ NOVARTIS PHARMA S.A.S. FR not available 15/0264/03-S NOVARTIS, S.R.O. SK NL/H/4274/001 PA 13/123/1 NOVARTIS PHARMACEUTICALS UK LIMED IE NL/H/4274/ NOVARTIS SVERIGE AB SE NL/H/4274/001 PL 00101/0935 NOVARTIS PHARMACEUTICALS UK LIMED UK not available 15/312/03-C NOVARTIS, S.R.O. CZ not available NOVARTIS PHARMACEUTICALS UK LIMED not available CHIESI FARMACEUTICI not available CHIESI FARMACEUTICI not available CHIESI FARMACEUTICI not available LT/1/11/2643/001 CHIESI PHARMACEUTICALS CY LT EMA/615391/2018 Page 4/9
5 BRAMOB 300 mg/4 ml šķīdums izsmidzināšanai BRAMOB 300 mg/4 ml otopina za atomizator Tobramycin "SUN", inhalationsvæske til nebulisator, opløsning Tobramycin SUN 300 mg Tobramycyna SUN, 300 mg/5 ml, roztwór do nebulizacji Tobramycine SUN 300 mg/5 ml verneveloplossing Tobramycin 300 mg/ 5 ml nebuliser solution Tobramicină SUN 300 mg soluţie pentru nebulizator Tobramicină SUN 300 mg soluţie pentru nebulizator not available LT/1/11/2643/002 CHIESI PHARMACEUTICALS not available LT/1/11/2643/003 CHIESI PHARMACEUTICALS not available CHIESI PHARMACEUTICALS not available UP/I /13-02/226 CHIESI PHARMACEUTICALS not available LT/1/11/2643/004 CHIESI PHARMACEUTICALS NL/H/3560/ SUN PHARMACEUTICAL NL/H/3560/ SUN PHARMACEUTICALS GERMANY NL/H/3560/ SUN PHARMACEUTICAL NL/H/3560/001 RVG SUN PHARMACEUTICAL NL/H/3560/001 PL 31750/0087 SUN PHARMACEUTICAL NL/H/3560/ /2017/01 SUN PHARMACEUTICAL NL/H/3560/ /2017/03 SUN PHARMACEUTICAL LT LT LV HR LT DK DE PL NL UK RO RO EMA/615391/2018 Page 5/9
6 Tobramicină SUN 300 mg soluţie pentru nebulizator Tobramicina SUN 300 mg/5 ml soluzione per Tobramicina SUN 300 mg/5 ml soluzione per Tobramicina SUN 300 mg/5 ml soluzione per Tobramicina SUN 300 mg/5 ml solución para inhalación por nebulizador Tobramicina Accord 300 mg/5 ml solución para inhalación por nebulizador Tobramicina Accord 300 mg/5 ml Solução para Inalação por Nebulização Tobramycin Teva 300 mg/5 ml Steri-Neb Tobramicina Teva 300 mg / 5 ml Soluzione per Tobramicina Teva 300 mg / 5 ml Soluzione per NL/H/3560/ /2017/02 SUN PHARMACEUTICAL NL/H/3560/ SUN PHARMACEUTICAL NL/H/3560/ SUN PHARMACEUTICAL NL/H/3560/ SUN PHARMACEUTICAL NL/H/3560/ SUN PHARMACEUTICAL PT/H/0504/ ACCORD HEALTHCARE S.L.U. PT/H/0504/ ACCORD HEALTHCARE LIMED UK/H/4346/ TEVA DE UK/H/4346/ TEVA ALIA S.R.L. UK/H/4346/ TEVA ALIA S.R.L. RO ES ES PT EMA/615391/2018 Page 6/9
7 Tobramicina Teva 300 mg / 5 ml Soluzione per Tobramycin 300 mg/5 ml Tobramycin Teva, inhalationsvæske til nebulisator, opløsning Tobramicina Teva, 300 mg/5 ml, Solução para Inalação por Nebulização Tobramicina Teva 300 mg/5 ml solución para inhalación por nebulizador Tymbrineb 300 mg/5 ml Tobramycine Steri-Neb 300 mg/5 ml, verneveloplossing 300 mg/5 ml 300 mg/5 ml šķīdums izsmidzināšanai 300 mg/5 ml nebuliseeritav lahus Тобрамицин Виа фарма 300 mg/5 ml разтвор за небулизатор UK/H/4346/ TEVA ALIA S.R.L. UK/H/4346/001 PL 00289/1437 TEVA UK LIMED UK UK/H/4346/ TEVA DENMARK A/S DK UK/H/4346/ TEVA PHARMA PRODUTOS FARMACÊUTICOS LDA UK/H/4346/ TEVA PHARMA S.L.U ES UK/H/4346/001 PA0749/117/001 TEVA PHARMA B.V. IE UK/H/4346/001 RVG TEVA NEDERLAND B.V. NL LT/H/0112/001 LT/1/16/3931/001 UAB VIA PHARMA LT LT/H/0112/ UAB VIA PHARMA LV LT/H/0112/ UAB VIA PHARMA EE LT/H/0112/ UAB VIA PHARMA BG PT EMA/615391/2018 Page 7/9
8 300 mg/ 5 ml oldat porlasztasra, 300 mg/5 ml, roztwór do nebulizacji 300 mg/5 ml soluţie pentru inhalare prin nebulizator BRAMOB, verneveloplossing 300 mg/4 ml BRAMOB 300 mg/4 ml TOBRINEB 300 mg/4 ml TOBRINEB 300 mg/4 ml TOBRINEB 300 mg/4 ml TOBRINEB 300 mg/4 ml BRAMOB 300 mg/4 ml Solución para inhalación por nebulizador Bramitob 300mg/4ml Bramitob 300mg/4ml LT/H/0112/001 OGYI-T-23038/01 UAB VIA PHARMA LT/H/0112/ UAB VIA PHARMA PL LT/H/0112/ /2016/01 UAB VIA PHARMA RO /H/0132/001 RVG CHIESI PHARMACEUTICALS B.V. /H/0132/ CHIESI DE /H/0132/ PROMEDICA S.R.L. /H/0132/ PROMEDICA S.R.L. /H/0132/ PROMEDICA S.R.L. /H/0132/ PROMEDICA S.R.L. /H/0132/ CHIESI ESPAÑA, S.A. ES /H/0132/001 PA 743/17/1 CHIESI LIMED IE /H/0132/001 PL 8829/0155 CHIESI LIMED UK NL EMA/615391/2018 Page 8/9
9 /H/0132/ CHIESI PHARMACEUTICALS BRAMOB /H/0132/001 15/214/07-C CHIESI PHARMACEUTICALS Bramitob 300 mg /4 ml oldat porlasztásra Bramitob 300 mg /4 ml oldat porlasztásra Bramitob 300 mg /4 ml oldat porlasztásra Bramitob 300 mg /4 ml oldat porlasztásra roztok na rozprašovanie BRAMOB 300 mg/ 4 ml Διάλυμα για εισπνοή με εκνεφωτή σε περιέκτη μίας δόσης Solução para inalação por nebulização Bramitob, 300 mg/4 ml, roztwór do nebulizacji /H/0132/001 OGYI-T /04 CHIESI PHARMACEUTICALS /H/0132/001 OGYI-T /01 CHIESI PHARMACEUTICALS /H/0132/001 OGYI-T /02 CHIESI PHARMACEUTICALS /H/0132/001 OGYI-T /03 CHIESI PHARMACEUTICALS /H/0132/001 15/0534/06-S CHIESI PHARMACEUTICALS /H/0132/ / CHIESI HELLAS A.E.B.E. GR /H/0132/ CHIESI FARMACEUTICI /H/0132/ CHIESI FARMACEUTICI AT CZ SK PT PL EMA/615391/2018 Page 9/9
List of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationList of nationally authorised medicinal products
11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary
More informationList of nationally authorised medicinal products
6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/00000883/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationList of nationally authorised medicinal products
28 September EMA/662335/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): levosalbutamol, salbutamol Procedure No.: PSUSA/00010330/201701 30
More informationEuropean Medicines Agency decision
EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)
More informationMember State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Union herbal monograph on Pistacia lentiscus L., resin (mastix)
7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationEUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008
European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium
More informationPublic administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective
Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationList of nationally authorised medicinal products
1 September 2017 EMA/593212/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): flurbiprofen Procedure No.: PSUSA/00001450/201611 30 Churchill
More informationEuropean Union herbal monograph on Peumus boldus Molina, folium
22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party
More information'SECTION B EU PARTY. The following abbreviations are used:
'SECTION B EU PARTY The following abbreviations are used: AT Austria BE Belgium BG Bulgaria CY Cyprus CZ Czech Republic DE Germany DK Denmark ES Spain EE Estonia EU European Union, including all its Member
More informationEuropean Union herbal monograph on Glycine max (L.) Merr., lecithinum
31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union
More informationEuropean Union herbal monograph on Ruscus aculeatus L. rhizoma
30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European
More informationPlease note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
More informationEuropean Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba
24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationTrends in injecting drug use in Europe
Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information
More informationEuropean Union herbal monograph on Symphytum officinale L., radix
5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE FINAL PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer 404 EUROPEAN CITIZENS DIGITAL HEALTH LITERACY SUMMARY Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationEuropean Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum
5 June 2018 EMA/HMPC/753041/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum Final Discussion in Working Party
More informationEuropean Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix
05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working
More informationEuropean Union herbal monograph on Agrimonia eupatoria L., herba
28 January 2015 EMA/HMPC/680597/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Agrimonia eupatoria L., herba Final Discussion in Working Party on European Union monographs
More informationEuropean Union herbal monograph on Helichrysum arenarium (L.) Moench, flos
29 September 2015 EMA/HMPC/41108/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos Draft Discussion in Working Party on European
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Medicines Agency decision
EMA/788583/2016 European Medicines Agency decision P/0363/2016 of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for dipalmitoylphosphatidylcholine
More informationEuropean Union herbal monograph on Hieracium pilosella L., herba cum radice
5 May 2015 EMA/HMPC/680374/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hieracium pilosella L., herba cum radice Final Discussion in Working Party on European Union
More informationSeptember 2014 January 2015 March 2015 May 2015 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation
7 July 2015 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis Draft
More informationEuropean Union herbal monograph on Hedera helix L., folium
21 November 2017 EMA/HMPC/325716/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hedera helix L., folium Final Initial assessment Discussion in Working Party on European
More informationEuropean Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma
21 November 2017 EMA/HMPC/329755/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), Draft Initial assessment Discussion in Working
More informationEuropean Union herbal monograph on Melilotus officinalis (L.) Lam., herba
28 March 2017 EMA/HMPC/44166/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Melilotus officinalis (L.) Lam., herba Draft Initial assessment Discussion in Working
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More informationLIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81
COUNCIL OF THE EUROPEAN UNION Brussels, 7 July 2011 12390/11 LIMITE ENFOPOL 228 DAPIX 81 NOTE From: Presidency To: Law Enforcement Working Party No. prev. doc.: CM 1508/11 Subject: Results of the questionnaire
More informationEuropean Union herbal monograph on Hedera helix L., folium
24 November 2015 EMA/HMPC/586888/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hedera helix L., folium Final Initial assessment Discussion in Working Party on European
More informationTransmission, processing and publication of HBS 2015 data
EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-4: Income and living conditions; Quality of life Doc. LC-ILC/194/17/EN estat.f.4 (2017) WORKING GROUP ON INCOME AND LIVING CONDITIONS
More informationDraft. Jul 2015 (MLWP) Discussion in Working Party on European Union monographs and list
27 March 2018 EMA/HMPC/432278/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa
More informationEnd of consultation (deadline for comments 1 ) 31 October 2015 Rediscussion in MLWP November 2015 Adoption by HMPC 2 February 2016
2 February 2016 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri
More informationEuropean Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix
05 June 2018 EMA/HMPC/737380/2018 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix Final Initial assessment Discussion in Working
More informationEuropean Union herbal monograph on Ribes nigrum L., folium
19 September 2017 EMA/HMPC/745353/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ribes nigrum L., folium Final Initial assessment Discussion in Working Party on European
More informationEuropean Medicines Agency decision
EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xolair 75 mg solution for injection Xolair 150 mg solution for injection Omalizumab
PACKAGE LEAFLET: INFORMATION FOR THE USER Xolair 75 mg solution for injection Xolair 150 mg solution for injection Omalizumab Read all of this leaflet carefully before you start using Xolair. - Keep this
More informationEnsuring protection of public health and patients in member states: priorities, constraints, opportunities
Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria
More informationEuropean Medicines Agency decision
EMA/120432/2017 European Medicines Agency decision P/0069/2017 of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M04) in
More informationEuropean Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix
2 February 2016 EMA/HMPC/627057/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix Draft - Revision
More informationEuropean Union herbal monograph on Echinacea purpurea (L.) Moench, radix
30 May 2017 EMA/HMPC/424583/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Echinacea purpurea (L.) Moench, radix Final Initial assessment Discussion in Working Party
More informationPharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH
PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline
More informationEuropean Medicines Agency decision
EMA/501292/2014 European Medicines Agency decision P/0227/2014 of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aliskiren (Rasilez and associated names),
More information